+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H1, 2018

  • ID: 4601582
  • Clinical Trials
  • Region: Global
  • 242 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • MORE
Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H1, 2018

Summary

The author's clinical trial report, “Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H1, 2018" provides an overview of Post-Traumatic Stress Disorder (PTSD) clinical trials scenario. This report provides top line data relating to the clinical trials on Post-Traumatic Stress Disorder (PTSD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Post-Traumatic Stress Disorder (PTSD)
  • May 31, 2018: Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
  • May 24, 2018: Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya or TNX-102 SL
  • May 07, 2018: Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
  • Apr 11, 2018: Phase 2 Clinical Trial of BNC210 For Treatment of Post traumatic Stress Disorder Fully Recruited
  • Apr 04, 2018: Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
  • Apr 03, 2018: Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
  • Mar 27, 2018: Study Shows Selenium Reduces PTSD Symptoms in Latvian Soldiers
  • Mar 13, 2018: Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Source
List of Tables
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Region, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, North America, Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018*
  • Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Region (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018*
  • Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Tonix Pharmaceuticals Holding Corp
  • Pfizer Inc
  • Allergan Plc
  • Tuscaloosa Research & Education Advancement Corp
  • Synthon Holdings BV
  • Premier Research Group Ltd
  • Otsuka Holdings Co Ltd
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
Adroll
adroll